secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2023-02-14T23:59:59+00:00
Accession:  0001558370-23-001236
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01, 99.1
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma delays Q2 FY2023 filing due to warrant accounting matter; believes no impact on revenue, cash, or EBITDA
--------------------------------------------------------------------------------

- Delayed filing of Form 10-Q for quarter ended Dec 31, 2022 pending management review of warrant accounting from prior financings.
- Company states the matter will not affect assets, cash, revenue, cost of goods sold, operating expenses, loss from operations, or adjusted EBITDA.
- Quarterly conference call rescheduled; company intends to file the quarterly report as soon as practicable.
- No restatement or adjustment to previously reported financial metrics expected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000155837023001236/0001558370-23-001236-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000155837023001236/aytu-20230214x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-001236

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer